Andreas Sashegyi

3.0k total citations
47 papers, 1.3k citations indexed

About

Andreas Sashegyi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Andreas Sashegyi has authored 47 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 18 papers in Pulmonary and Respiratory Medicine and 11 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Andreas Sashegyi's work include Lung Cancer Treatments and Mutations (12 papers), Estrogen and related hormone effects (11 papers) and Colorectal Cancer Treatments and Studies (9 papers). Andreas Sashegyi is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Estrogen and related hormone effects (11 papers) and Colorectal Cancer Treatments and Studies (9 papers). Andreas Sashegyi collaborates with scholars based in United States, Germany and Spain. Andreas Sashegyi's co-authors include Elizabeth Barrett‐Connor, Pamela W. Anderson, David A. Cox, Kristine D. Harper, Deborah Grady, K Hoszowski, for the RED-CABG Steering Committee and Investigators, Pentti M. Rautaharju, David Ferry and Jane A. Cauley and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Andreas Sashegyi

46 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andreas Sashegyi United States 17 592 473 387 236 233 47 1.3k
Roberta J. Secrest United States 16 529 0.9× 500 1.1× 315 0.8× 259 1.1× 136 0.6× 27 2.5k
Michelle McNabb United States 6 521 0.9× 508 1.1× 242 0.6× 610 2.6× 82 0.4× 6 1.3k
J. E. Glusman United States 10 1.1k 1.9× 794 1.7× 751 1.9× 318 1.3× 100 0.4× 17 2.1k
Vibeke R. Gerkins United States 8 446 0.8× 307 0.6× 316 0.8× 254 1.1× 117 0.5× 9 1.2k
Anne Irene Hagen Norway 16 608 1.0× 564 1.2× 107 0.3× 131 0.6× 93 0.4× 31 1.2k
Sheryl L. Silfen United States 14 442 0.7× 318 0.7× 157 0.4× 157 0.7× 87 0.4× 25 994
Richard Eastell United Kingdom 18 731 1.2× 788 1.7× 352 0.9× 1.0k 4.3× 97 0.4× 29 2.0k
George Christodoulakos Greece 21 240 0.4× 173 0.4× 384 1.0× 98 0.4× 76 0.3× 55 1.3k
Aarti S. Shah United States 8 1.0k 1.8× 553 1.2× 614 1.6× 589 2.5× 37 0.2× 11 1.6k
Alwynne Tidy United Kingdom 11 1.2k 2.0× 1.5k 3.1× 185 0.5× 312 1.3× 284 1.2× 17 2.2k

Countries citing papers authored by Andreas Sashegyi

Since Specialization
Citations

This map shows the geographic impact of Andreas Sashegyi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andreas Sashegyi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andreas Sashegyi more than expected).

Fields of papers citing papers by Andreas Sashegyi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andreas Sashegyi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andreas Sashegyi. The network helps show where Andreas Sashegyi may publish in the future.

Co-authorship network of co-authors of Andreas Sashegyi

This figure shows the co-authorship network connecting the top 25 collaborators of Andreas Sashegyi. A scholar is included among the top collaborators of Andreas Sashegyi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andreas Sashegyi. Andreas Sashegyi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Goto, Kōichi, J. Wolf, Yasir Y. Elamin, et al.. (2021). FP14.05 LIBRETTO-431: Selpercatinib in Treatment-Naïve Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC).. Journal of Thoracic Oncology. 16(3). S228–S229. 5 indexed citations
2.
Solomon, Benjamin, Alexander Drilon, Keunchil Park, et al.. (2020). Phase III Study of Selpercatinib Versus Chemotherapy ± pembrolizumab in Untreated RET Positive Non-Small-Cell Lung Cancer. Future Oncology. 17(7). 763–773. 30 indexed citations
3.
Hernando, Jorge, Mimi I. Hu, Eric J. Sherman, et al.. (2020). 1927TiP LIBRETTO-531: Selpercatinib in patients with treatment (Tx)-naïve RET-mutant medullary thyroid cancer (MTC). Annals of Oncology. 31. S1091–S1091. 3 indexed citations
4.
Roeland, Eric, Ran Wei, Anindya Chatterjee, et al.. (2019). Analysis of weight loss as a prognostic factor in patients with advanced gastric cancer from the Phase 3 RAINBOW study. Annals of Oncology. 30. iv111–iv111. 1 indexed citations
5.
Reck, Martin, Marina Chiara Garassino, Martina Imbimbo, et al.. (2018). Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting. Lung Cancer. 120. 62–69. 23 indexed citations
6.
7.
8.
Sashegyi, Andreas, et al.. (2016). Comment on: Risk of gastrointestinal perforation in cancer patients receiving ramucirumab: a meta-analysis of randomized controlled trials. Journal of Chemotherapy. 29(1). 62–64. 5 indexed citations
9.
10.
Lindborg, Stacy, et al.. (2014). Statistical refocusing in the design of Phase II trials offers promise of increased R&D productivity. Nature Reviews Drug Discovery. 13(8). 638–640. 17 indexed citations
11.
Sashegyi, Andreas. (2011). A benefit-risk Model to Facilitate DMC-sponsor Communication and Decision Making. Drug Information Journal. 45(6). 749–757. 4 indexed citations
12.
Sashegyi, Andreas. (2008). Adaptive Design and Decision Analysis—Companions for Transforming Clinical Development. Drug Information Journal. 42(4). 331–336. 2 indexed citations
13.
Laterre, Pierre‐François, David R. Nelson, William L. Macias, et al.. (2007). International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safety. Journal of Critical Care. 22(2). 142–152. 15 indexed citations
14.
Sashegyi, Andreas, Benjamin Trzaskoma, David R. Nelson, Mark D. Williams, & William L. Macias. (2006). International INtegrated Database for the Evaluation of severe sePsis and drotrecogin alfa (activated) THerapy: component trials and statistical methods for INDEPTH. Current Medical Research and Opinion. 22(5). 1001–1012. 8 indexed citations
15.
Keech, Cheryl, Andreas Sashegyi, & Elizabeth Barrett‐Connor. (2005). Year-by-year analysis of cardiovascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial. Current Medical Research and Opinion. 21(1). 135–140. 18 indexed citations
16.
Barrett‐Connor, Elizabeth, Jane A. Cauley, Pandurang M. Kulkarni, et al.. (2004). Risk-Benefit Profile for Raloxifene: 4-Year Data From the Multiple Outcomes of Raloxifene Evaluation (MORE) Randomized Trial. Journal of Bone and Mineral Research. 19(8). 1270–1275. 55 indexed citations
17.
18.
Barrett‐Connor, Elizabeth, Deborah Grady, Andreas Sashegyi, et al.. (2002). Raloxifene and Cardiovascular Events in Osteoporotic Postmenopausal Women. JAMA. 287(7). 847–847. 427 indexed citations
19.
Lippman, Marc E., Kathryn A. Krueger, Stephen Eckert, et al.. (2001). Indicators of Lifetime Estrogen Exposure: Effect on Breast Cancer Incidence and Interaction With Raloxifene Therapy in the Multiple Outcomes of Raloxifene Evaluation Study Participants. Obstetrical & Gynecological Survey. 56(11). 698–700. 5 indexed citations
20.
Walsh, Brian W., David A. Cox, Andreas Sashegyi, et al.. (2001). Role of tumor necrosis factor-α and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women. The American Journal of Cardiology. 88(7). 825–828. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Roberta J. Secrest Breakdown of academic impact, for papers by Michelle McNabb Breakdown of academic impact, for papers by J. E. Glusman Breakdown of academic impact, for papers by Vibeke R. Gerkins Breakdown of academic impact, for papers by Anne Irene Hagen Breakdown of academic impact, for papers by Sheryl L. Silfen Breakdown of academic impact, for papers by Richard Eastell Breakdown of academic impact, for papers by George Christodoulakos Breakdown of academic impact, for papers by Aarti S. Shah Breakdown of academic impact, for papers by Alwynne Tidy
Rankless by CCL
2026